Healthcare Stock Could Be Good 'Buy the Dip' Play
The shares of healthcare name Hims & Hers Health Inc (NYSE:HIMS) have retreated from their Feb. 19, pre-earnings all-time high of $72.98.
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
Hims & Hers Health, Inc. HIMS stock is trading lower on Wednesday, with a session volume of 7.7 million compared to the average volume of 19.34 million, as per data from Benzinga Pro.
Hims & Hers: A Generational Dip-Buying Opportunity
HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While bears focus on waning GLP-1 sales, HIMS' business outside GLP-1s is still growing rapidly.
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (HIMS 9.07%) plummeted following its fourth-quarter earnings report. The stock had rocketed from around $24 at the start of the year to over $70 before pulling back.
Why Hims & Hers Health Stock Sank This Week
Shares of Hims & Hers Health (HIMS 6.76%) sank 10.5% this week, according to data from S&P Global Market Intelligence. The telehealth company that sells dermatology, sexual health, and weight loss drugs directly to consumers posted strong growth for the fourth quarter of 2024 but has investors concerned over the legality of its weight loss drug compounds.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers: Shortage-Driven Sell-Off Appears Overdone; Buy
Hims and Hers' stock dropped 25% due to the end of the semaglutide shortage, but the sell-off is seen as exaggerated. Despite the setback, Hims and Hers continue to show strong subscriber growth and profitability, with a 269.49% increase since December 2021. The company benefits from political support and a $5 billion market cap boost post-Super Bowl, indicating potential for explosive growth.
Why Hims & Hers Stock Rebounded on Wednesday
Hims & Hers (HIMS 5.09%) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the week. Several analysts raised their price targets on the specialty healthcare company on that slump, which helped Hims & Hers recover by more than 5% in mid-week action.
Hims & Hers: Down 45% In 5 Days, Is The Stock Still A Buy?
Hims & Hers Health is a promising disruptor in the $4T US healthcare market, aiming to become the most trusted health & wellness brand. Despite recent stock volatility, Hims & Hers' Q4 2024 report showed strong growth, with revenues up 95% y/y and robust 2025 guidance. The end of semaglutide compounding poses challenges, but Hims & Hers is expected to maintain growth through diversified offerings and new specialties.
Wall Street's Most Wanted: 2 Highly Shorted Stocks Right Now
Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling shares short are hoping that the price of certain stocks falls so that they can make a profit.
HIMS Stock Craters – Is It a Buying Opportunity?
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn't guarantee it would be able to continue selling its knockoff versions of weight-loss drugs Ozempic and Wegovy.
